Today: 30 June 2026
Browse Category

NYSE:ROK 2 July 2025 - 25 February 2026

Edge Computing Global News & Trends Roundup (June–July 2025)

Edge Computing Global News & Trends Roundup (June–July 2025)

Coverage: This report highlights global developments in edge computing from June 1, 2025 through early July 2025, including regional news, industry-specific trends, market forecasts, and expert insights. North America: Edge computing momentum in North America remained strong. U.S. telecom operators rolled out new 5G multi-access edge computing services. For example, Verizon Business launched an Edge Transportation Exchange – a V2X platform leveraging 5G and mobile edge computing for real-time data sharing between vehicles, infrastructure, and pedestrians edgeir.com. The platform enables road safety use cases without expensive roadside units by using a virtualized edge architecture edgeir.com. Key deployments are underway with partners like Volkswagen, state transportation departments and universities to improve connected traffic systems. As Verizon’s VP Shamik Basu noted, “Cars are evolving from mechanical vehicles to software-defined mobile devices… Edge [technology] gives automakers, governments, and developers a robust platform for the cellular-connected future of transportation” edgeir.com. In industrial tech, Rockwell Automation introduced OptixEdge, an advanced gateway to process factory machine data on-site. By doing so, it reduces reliance on cloud servers and improves efficiency for smart manufacturing operations edgeir.com. According to Rockwell’s latest report, today’s smart machines generate massive data yet only 44% of it is used effectively – a
2 July 2025
·······

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop